Literature DB >> 26033438

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

Enrique M Ocio1, Albert Oriol2, Joan Bladé3, Ana I Teruel4, Jesus Martín5, Javier de la Rubia6, Norma C Gutiérrez7, José Rodríguez Díaz-Pavón8, Sara Martínez González8, Cinthya Coronado8, Eva M Fernández-García8, Mariano Siguero Gómez8, Carlos Fernández-Teruel8, Jesus San Miguel9.   

Abstract

Entities:  

Keywords:  PM00104; dexamethasone; multiple myeloma; phase I/II

Mesh：

Substances：

Year:  2015        PMID： 26033438     DOI： 10.1111/bjh.13515

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

Authors:  Ana-Alicia López-Iglesias; Lorena González-Méndez; Laura San-Segundo; Ana B Herrero; Susana Hernández-García; Montserrat Martín-Sánchez; Norma C Gutiérrez; Teresa Paíno; Pablo Avilés; María-Victoria Mateos; Jesús F San-Miguel; Mercedes Garayoa; Enrique M Ocio
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

2.  Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.

Authors:  Niels van Nieuwenhuijzen; Rowan Frunt; Anne M May; Monique C Minnema
Journal:  Blood Cancer J       Date:  2021-03-01       Impact factor: 11.037

Review 3.  Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.

Authors:  Marilia Barreca; Virginia Spanò; Alessandra Montalbano; Mercedes Cueto; Ana R Díaz Marrero; Irem Deniz; Ayşegül Erdoğan; Lada Lukić Bilela; Corentin Moulin; Elisabeth Taffin-de-Givenchy; Filippo Spriano; Giuseppe Perale; Mohamed Mehiri; Ana Rotter; Olivier P Thomas; Paola Barraja; Susana P Gaudêncio; Francesco Bertoni
Journal:  Mar Drugs       Date:  2020-12-04       Impact factor: 5.118

Review 4.  Multiple Myeloma: Possible Cure from the Sea.

Authors:  Anita Capalbo; Chiara Lauritano
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.